Upfront Briefing
Trump signed an executive order that could impose tariffs of up to 100% on some imported branded drugs — a fast way to turn COGS into a board-level topic.
Elsewhere: Vericel picked up a BARDA award valued at up to $197M for NexoBrid, while Immunovant’s batoclimab failed two Phase 3 thyroid eye disease trials, pushing the FcRn story back under the microscope.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,582.7 |
+0.1% |
(4.0%) |
| Nasdaq 100 |
24,045.5 |
+0.1% |
(4.6%) |
| Russell 2000 |
2,530.0 |
+0.7% |
+0.9% |
| Healthcare (XLV) |
146.8 |
(0.6%) |
(5.2%) |
| Biotech (XBI) |
129.0 |
+0.3% |
+6.1% |
| Nasdaq Biotech (NBI) |
5,852.5 |
(0.4%) |
+2.6% |
| Clinical Trials (BBC) |
42.8 |
+1.0% |
+13.8% |
|
- Broader indices finished mixed, but biotech again held its relative bid: XBI rose +0.3% even as XLV fell (0.6%), suggesting investors kept leaning toward idiosyncratic growth and deal-driven names rather than defensive healthcare beta.
- Small caps outperformed, with the Russell 2000 up +0.7%, while oil stayed elevated after Trump signaled continued military action in Iran — a backdrop that likely capped enthusiasm for longer-duration mega-cap growth even as biotech remained selective rather than risk-off.
- Standout mover: Clinical Trials (BBC) outperformed again, consistent with capital rotating toward higher-beta development-stage biotech after a week of improving sector sentiment and heavier dealflow.
- Market data: U.S. close Thu 02-Apr-2026.
The Big 3
|
1
|
Trump signs order imposing up to 100% tariffs on some imported branded drugs
|
- Trump signed an executive order that could impose tariffs of up to 100% on some imported patented drugs, with lower rates or exemptions tied to U.S. manufacturing buildout and White House pricing agreements. Generics are broadly carved out, and companies have roughly 120–180 days before enforcement depending on size.
- Why it matters: For investors, this is not a simple “pharma tariff” headline — it is a gross-margin, supply-chain and capital-allocation screen. The highest exposure sits with branded products manufactured ex-U.S. without negotiated exemptions, while better-insulated names are those with domestic capacity, favorable geography, or enough pricing flexibility to absorb higher landed cost. The first-order hit is COGS; the second-order question is whether management teams now have to accelerate onshoring, dual-sourcing and contract renegotiation faster than planned.
- Source: Reuters
- More: Endpoints; STAT
|
|
2
|
Vericel wins BARDA award up to $197M for NexoBrid
|
- Vericel announced a BARDA award valued at up to $197 million for procurement and advanced development of NexoBrid. The contract could improve revenue visibility tied to the program.
- Why it matters: NexoBrid is already a commercial-stage burn asset, so this is more than grant optics. The BARDA award supports procurement plus advanced development, which should improve revenue visibility, extend the product’s strategic relevance in U.S. preparedness planning, and fund program work with non-dilutive capital rather than balance-sheet cash. For investors, that lowers financing burden around the asset while reinforcing that severe-burn infrastructure can still attract federal dollars when clinical utility is already established.
-
Source:
PR
-
More:
PR
|
3 |
Immunovant’s batoclimab flunks two Phase 3 thyroid eye disease trials |
- Immunovant said batoclimab failed to meet the primary endpoint in two Phase 3 thyroid eye disease trials, and management said the results do not support further development of the asset in TED. The company is shifting focus toward next-generation FcRn inhibitor IMVT-1402.
- Why it matters: This is not just a single-study miss — it effectively closes off TED as a value-creation path for batoclimab and sharpens the market’s focus on whether IMVT-1402 can carry the FcRn thesis forward. For investors, the read-through is twofold: first, TED remains a harder commercial and clinical market than many hoped; second, within FcRn, molecule-specific differentiation still matters, so platform enthusiasm does not fully protect individual assets from sharp repricing after pivotal failure.
-
Source:
Reuters
-
More:
Fierce Biotech
|
Everything Else that broke
- White House in talks on drug-pricing deals with small drugmakers. — STAT
- DOJ backs pharma in 340B contract pharmacy dispute. — Endpoints
- Cipla wins FDA approval for nintedanib capsules for IPF. — PR
- BioCentury flags April PDUFA dates, including Replimune and Grace. — BioCentury
- Alto halted work on ALTO-101 after the PDE4 inhibitor failed to show a statistically significant benefit in a Phase 2 proof-of-concept study in cognitive impairment associated with schizophrenia. — Fierce Biotech
- Regeneron partners with TriNetX to access de-identified EHR data from 300M patients. — PR
- Serina: NYSE American accepts continued listing compliance plan. — PR
- Shreehas Tambe named first CEO of newly combined Biocon. — BioCentury
- BioCentury: teams converge on RNU2-2 as a targetable node in neurodevelopmental epilepsies. — BioCentury
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
OpenLoop Health acquires Season Health, adding food-as-medicine and dietitian-led nutrition support to its telehealth infrastructure stack. — Endpoints
-
Regeneron teams with TriNetX for access to de-identified EHRs from 300M patients, with an exclusive option to link parts of that dataset to Regeneron-generated genomic and proteomic cohorts. — PR
VC / Private Financings
- Aspect Biosystems secured C$79M from the Government of Canada to support its bioprinted tissue therapeutics platform and diabetes cell-therapy manufacturing buildout; strategic context includes its expanded Novo Nordisk partnership. — Gov. of Canada
- Syneron Bio completed a $150M Series B to advance its macrocyclic peptide platform and pipeline; syndicate includes ARCH Venture Partners, NVentures, Eli Lilly and Company, and Alexandria Venture Investments. — PR
IPOs / Follow-Ons
- INOVIO priced a $17.5M underwritten public offering of common stock and warrants, with closing expected April 6. — PR
- Arch Biopartners closed a non-brokered private placement of 1.0M shares at C$0.60 for gross proceeds of C$600K. — PR
Things that make you go hmmm ...
Biopharma Equity Investments ($B). Source: UBS.
Academic Corner - Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. — Nature Medicine
- FDA approves GLP-1 pill for obesity. — Nature RDD
- Medicare Spending Implications for Semaglutide Under Voluntary Price Agreements. — JAMA
|
